Health

MindRank Announces $52 Million Series B Financing

HANGZHOU, China, July 09, 2026 (GLOBE NEWSWIRE) -- MindRank AI Ltd. (“MindRank”), a clinical-stage biotechnology company dedicated to building an…

6 days ago

Outliyr’s Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power

Outliyr's free public database catalogs more than seventy red light therapy panels and other light therapy devices, and publishes its…

1 week ago

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming…

1 week ago

Range Impact Announces Vin Ferrara, MD, MBA, Has Joined the Company as Vice President, Real Estate

CLEVELAND, OHIO, July 08, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public…

1 week ago

Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of…

1 week ago

TaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in Taiwan

July 07, 2026 19:00 ET  | Source: TaiMed Biologics TAIPEI, July 07, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147)…

1 week ago

Resmed Announces Agreement to Sell MatrixCare Business

SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on…

1 week ago

Presentation of New Clinical Data on Givinostat in Duchenne Muscular Dystrophy at ICNMD 2026

Phase 3 EPIDYS MRI data quantify givinostat’s potential to preserve functional muscle tissue and reduce fat infiltration in patients with…

1 week ago

ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs

Investigational n.c.a. 177Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective response rate vs. everolimus Garching / Munich, July…

1 week ago

Levicept Appoints Darlene Deptula-Hicks as CFO

Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis July 07,…

1 week ago